Hollis, Robert L. http://orcid.org/0000-0002-1390-3298
Thomson, John P.
Stanley, Barbara
Churchman, Michael
Meynert, Alison M.
Rye, Tzyvia
Bartos, Clare
Iida, Yasushi
Croy, Ian
Mackean, Melanie
Nussey, Fiona
Okamoto, Aikou
Semple, Colin A. http://orcid.org/0000-0003-1765-4118
Gourley, Charlie http://orcid.org/0000-0002-2377-7221
Herrington, C. Simon http://orcid.org/0000-0001-9177-8165
Funding for this research was provided by:
RCUK | Medical Research Council
Article History
Received: 2 March 2020
Accepted: 11 September 2020
First Online: 5 October 2020
Competing interests
: M.M.: honoraria from Tesaro, BristolMyersSquibb and Roche. F.N.: non-personal interests in AstraZeneca and Tesaro. C.G.: discloses research funding from AstraZeneca, Aprea, Nucana, Tesaro and Novartis; honoraria/consultancy fees from Roche, AstraZeneca, M.S.D., Tesaro, Nucana, Clovis, Foundation One, Cor2Ed and Sierra Oncology; named on issued/pending patents related to predicting treatment response in ovarian cancer outside the scope of the work described here. All other authors declare no conflicts of interest.